戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 -by-side in vitro FcgammaR-binding analyses, cell-based ADCC assays, and in vivo IgG-mediated cellula
2 merged as a promising cell type for use as a cell-based adjunct immunosuppressive therapy in solid or
3 B) and chimeric antigen receptor (CAR) for T-cell-based adoptive cell transfer are among these develo
4 quantify agonist receptor selectivity, bias, cell-based agonism, and the effects of receptor mutation
5 ombination of chemical, genetic, genomic and cell-based analyses.
6                       Using a combination of cell-based and biophysical assays together with structur
7    Importantly, experimental validation with cell-based and in vitro ATPase assays confirmed three (e
8                   This involved biochemical, cell-based, and tier-one ADME techniques.
9 roach, a downscaled luciferase reporter gene cell-based anti-AR-CALUX assay and LC-HRMS/MS nontarget
10 been hindered by the limitations of existing cell based approaches.
11                                        Using cell-based approaches and mouse models of Mtb infection,
12 f selected recent reports of stem/progenitor cell-based approaches for retinal disease, with interpre
13            Here, we combined biochemical and cell-based approaches to uncover a dual pathogenic mecha
14 l-based assay (1.5%), and in CSF controls by cell-based assay (0.9%).
15 rum controls by tissue-based assay (0.5%) or cell-based assay (1.5%), and in CSF controls by cell-bas
16 cosylation significantly decreased ADCC in a cell-based assay and suppressed antibody-mediated cell k
17                           Thereby a complete cell-based assay for efficient drug screening is perform
18                 We have established an NK-92 cell-based assay for IFN-gamma release, identified resid
19 hable kinases, we established an all-optical cell-based assay for screening inhibitors, uncovered a d
20 g of the endogenous LGI4 transcript and in a cell-based assay impaired the secretion of truncated LGI
21                                              Cell-based assay supports the physiological relevance of
22                  Here we describe a reporter cell-based assay to quantify inducible, replication-comp
23  assay, and selectively inhibited SOAT1 in a cell-based assay using SOAT1-/SOAT2-CHO cells.
24 rse chemical structures was screened using a cell-based assay.
25 ed phosphorylation of the EphA4 protein in a cell-based assay.
26             Tau prions were measured using a cell-based assay.
27             Together these data suggest that cell based assays can reveal subtle but clinically relev
28                                              Cell based assays demonstrated that the optimized inhibi
29 it nanomolar potency in both biochemical and cell based assays.
30                                              Cell-based assays also indicate that bVP24 exhibits decr
31 ve similarly to ZMC1 in both biophysical and cell-based assays and are heretofore named ZMC2 (NSC3197
32 their biologic properties were determined in cell-based assays and confocal microscopy.
33 annel blocking ability were determined using cell-based assays and two-electrode voltage clamp (TEVC)
34 nterest in the HIV vaccine field but current cell-based assays are usually difficult to reproduce acr
35 e National Cancer Center were analysed using cell-based assays for MOG-IgG and aquaporin-4 immunoglob
36 excitotoxicity, hindering the development of cell-based assays for NMDAR drug discovery.
37 with first-episode psychosis using classical cell-based assays in three labs and a single molecule-ba
38     Biophysical analyses in combination with cell-based assays indicate that hRpn13 binds preferentia
39  interacting ArfGAP 1) gene using functional cell-based assays involving coexpression of GIT1 and PAK
40                                 In vitro and cell-based assays revealed that the CNAbeta1-containing
41                  Traditional methods rely on cell-based assays that lack reproducibility and accuracy
42                                              Cell-based assays to assess the effect of ADH-41 on Abet
43       We tested all four TSCs in a number of cell-based assays to examine mutant p53 reactivation and
44        We used surface plasmon resonance and cell-based assays to investigate this important IFN-beta
45          However, some heterogeneity between cell-based assays was clearly observed, highlighting the
46 nst norovirus 3C-like protease in enzyme and cell-based assays was determined.
47 125)I-alphaDTX-labelled Kv1 subunits, and by cell-based assays which expressed Kv1 subunits, LGI1 and
48  SHMT in target assays and PfNF54 strains in cell-based assays with values in the low nanomolar range
49 AT3 with selectivity over STAT5 and STAT1 in cell-based assays, and increases the apoptotic rate of c
50 itional repair function of NONO, revealed in cell-based assays, could involve RNA interaction.
51 alidate mitoxantrone in orthogonal mammalian cell-based assays, demonstrating that our screening appr
52                    In recent years, in vitro cell-based assays, ex vivo palate cultures, and genetica
53 mined the function of these structures using cell-based assays, in vitro translation systems, and in
54 ryptic inhibited ligand signaling in various cell-based assays, including SMAD-mediated luciferase re
55                                              Cell-based assays, like the cellular antioxidant activit
56                 In CME and growth inhibition cell-based assays, the data obtained was consistent with
57 y, which we demonstrate biochemically and in cell-based assays.
58 characterized using different approaches and cell-based assays.
59 t also apply to drug studies with other stem cell-based assays.
60 zers, which was confirmed experimentally via cell-based assays.
61 AP isoforms (alpha, varepsilon, or kappa) by cell-based assays; and (3) clinical data available.
62 g interface was confirmed by a comprehensive cell-based binding assay against a library of CTLA-4 mut
63  Based on these structures and complementary cell-based, biochemical, and molecular dynamics approach
64  expand the possibility of clinical in vitro cell based biological assays for various pulmonary disea
65 bination of an organic drug synthesis with a cell-based biological activity testing system, require a
66        Here we describe for the first time a cell-based BLI (cBLI) application that allows label-free
67 ld-seeded cells is still a challenge in stem cell-based bone regeneration.
68 on and that 25(OH)D3 has great potential for cell-based bone tissue engineering.
69                 Many promising targets for T-cell-based cancer immunotherapies are self-antigens.
70 erapy for leukemia and new, more specific NK cell-based cancer therapies.
71                                 This primary cell-based co-culture system combined with microOCT imag
72                                           In cell-based culture and brain metastasis models, we found
73 hibitors is a critical step for interpreting cell-based data and guiding inhibitor optimization.
74 e, we present structural, spectroscopic, and cell-based data supporting a novel copper-induced mechan
75 oscopy approach, multiplex immunofluorescent cell-based detection of DNA, RNA and Protein (MICDDRP),
76                                         Stem cell-based disease modeling is an emerging technology fo
77 ility of the developed solvent exchanger for cell based downstream applications was proven.
78                                         This cell-based driven SAR produced compounds with strong sin
79 Using chemical proteomics and an organotypic cell-based drug screening assay, we determine the functi
80                                      Using a cell-based drug-screening assay, we identified Acriflavi
81                                  As shown in cell-based dual-luciferase reporter gene assays, functio
82 igens by FACS analysis and a newly developed cell-based ELISA.
83 ation and for the future development of stem-cell-based engineered T cell therapies.
84   As a result, it fills an urgent need for a cell-based EPAC assay that can be conveniently performed
85                           A reverse genetics cell-based evaluation of genes linked to healthy human t
86 hese epidemics are replicated using a simple cell-based experimental setup where the rate of evolutio
87                        We developed a single cell-based experimental system from Arabidopsis (Arabido
88                               Confirming the cell-based experiments, we found deficient LH3-specific
89          Studies of PORCN activity relied on cell-based fatty acylation and signaling assays as no di
90 forced by protein-protein binding and single cell-based flagellar motor switching analyses.
91 and tested as SGLT1/SGLT2 inhibitors using a cell-based fluorescence assay of glucose uptake.
92                                              Cell-based fluorescence reporter assays in Escherichia c
93 ed libraries to find compounds that act on a cell-based fluorescence sensor of ppGalNAc-T3 but not on
94 onfirmed through independent replication and cell-based functional assays.
95                          In combination with cell-based functional studies, our data suggest that the
96 t two-hybrid (HT-eY2H) assay and a mammalian-cell-based Gaussia princeps luciferase protein-fragment
97                    In the field of dendritic cell based genetic immunization, previously we showed th
98 d application of TGx-DDI for high-throughput cell-based genotoxicity testing using nCounter technolog
99                                      Using a cell-based GR activity assay that measures Dexamethasone
100                                          The cell-based H2O2 generation is affected by the medium vol
101 5-bromo-2-methoxybenzyl) amine (ABMA) from a cell-based high throughput screening for its capacity to
102                                Here, through cell-based high throughput screening we identified benza
103 ments are urgently required, however current cell-based high-throughput screening (HTS) models to ide
104 ia against novel compounds isolated by whole-cell-based high-throughput screening (HTS).
105                       In this study, using a cell-based high-throughput screening model representing
106 could activate multiple TLRs, we performed a cell-based high-throughput screening of a small-molecule
107     To address this challenge, we employed a cell-based, high-throughput method using a luciferase re
108                                              Cell-based HRT (cHRT) is an alternative approach that ma
109 ously demonstrated lactational transfer of T cell-based immunity from dam to foster pup.
110                                        Using cell-based immunoprecipitation with plasma from cGVHD pa
111 eveloped a genetically adjuvanted, dendritic cell-based immunotherapeutic for acute Chagas disease in
112 rofound implications in the development of T cell-based immunotherapeutic strategies to treat blindin
113          In this study, we developed a CAR T cell-based immunotherapeutic strategy to target TEM8, a
114  routine delivery of cell products, has made cell-based immunotherapeutics a real prospect for cancer
115 nhibitors.Many patients fail to respond to T cell based immunotherapies.
116                                            T cell-based immunotherapies are a promising approach for
117                                            T-cell-based immunotherapies are promising treatments for
118 n-presenting cells in current development as cell-based immunotherapies, including Tol-DC, Rapa-DC, D
119 alter the vulnerability of cancer cells to T-cell-based immunotherapies.
120 onserved mechanisms, which may explain why T-cell-based immunotherapy can provide durable benefits wi
121 immune mechanisms and confer resistance to T-cell-based immunotherapy.
122  into tumors, and enhanced the efficacy of T-cell-based immunotherapy.
123 ould find sensible application in adoptive T cell-based immunotherapy.
124 vocal radiologic complete regression after T-cell-based immunotherapy.
125       For these studies, we created a novel, cell-based in vivo system for study of wild-type and var
126                             First: a new red-cell-based index, Joint Indicator A, to discriminate bet
127 eration, the African spiny mouse, to examine cell-based inflammation and tested the hypothesis that m
128 pment of compounds with potent enzymatic and cell-based inhibition of LDH enzymatic activity.
129 t attribute to consider for obtaining potent cell-based inhibition of this cancer metabolism target.
130                         The structure-guided cell-based inhibition studies further demonstrate that t
131 ulation devices have the potential to enable cell-based insulin replacement therapies (such as human
132                                 In order for cell-based insulin replacement to be applied as a treatm
133 will compromise the therapeutic potential of cell-based insulin replacement.
134 ls from clinical trials, for stem/progenitor cell-based interventions for retinal disease.
135                              Stem/progenitor cell-based interventions have the potential to address b
136             Preclinical studies suggest that cell-based interventions may influence functional recove
137                              Stem/progenitor cell-based interventions represent a novel class of pote
138 m and long-term safety and efficacy of these cell-based interventions.
139                                        Using cell-based knockdown approaches and microarray analyses
140                                              Cell-based luciferase assays showed that the engineered
141                                 We propose a cell-based mathematical model of tissue growth to invest
142 ication of off-target sites with independent cell-based measurements of activity at those sites when
143 a showed that the rapidly deployed CX3CR1(+) cell-based mechanism of immune exclusion is a defense me
144         In this report, the development of a cell-based, medium to high throughput screening assay th
145                               Artificial and cell-based membrane permeability assays provided evidenc
146                             As compared to a cell-based method, the described technique is rapid, qua
147                   Using both biochemical and cell-based methods to assess Galpha-RGS complex formatio
148 vered, and steady-state analysis followed by cell-based microarray genome-wide model validation led t
149 onal tools to prioritize VUS and developed a cell-based minigene splicing assay to confirm aberrant s
150 , ligand-copper complexes were examined in a cell-based model and were found to prevent BoNT/A cleava
151 s) accumulated in LB-like inclusions in this cell-based model as well as in a mouse model of LB disea
152 logues demonstrated inhibitory activity in a cell-based model for SNAP-25 cleavage and an ex vivo ass
153 idene-N-retinylethanolamine elimination in a cell-based model of macular degeneration.
154                           In an in vitro and cell-based model of MMP-dependent breast cancer cellular
155                                      Using a cell-based model of pathogenic huntingtin expression, we
156                   In an in vitro endothelial cell-based model of the blood-brain barrier, we confirme
157 enetic regulators of PGRN levels in a rodent cell-based model system.
158 re, the authors use a human pluripotent stem cell-based model, termed the post-implantation amniotic
159                     To this end a variety of cell-based modelling approaches have been developed, ran
160 ability of an implementation of five popular cell-based modelling approaches within a consistent comp
161                                    Mouse and cell-based models demonstrate that commensal GPR119 agon
162 format and may be widely applied to in vitro cell-based models in which matrix protein deposition ref
163 tenuates adipogenesis in various genetic and cell-based models.
164                                            A cell-based MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-dipheny
165  865) were evaluated by tissue (n = 542) and cell-based (n = 323) assays.
166 etastatic tumors, especially when exploiting cell-based nanotherapies.
167 -real-time, here we introduce a novel single-cell based nanotool termed dual biomembrane force probe
168 tive CNS neurons, which is critical for stem cell-based neural pathway regeneration.
169 ADH) is a possible hydride source inside the cell based on studies using pyruvate as a cellular redox
170 mbrane-free enzymatic glucose/oxygen biofuel cell based on transparent and nanostructured conducting
171 d outdoor stability testing of organic solar cells based on a blend between a donor-acceptor polyfluo
172 em that controls the firing mode of thalamic cells based on attentional demand.
173  system to recognize and eliminate malignant cells based on differential antigen expression.
174 pathways and the AKT/FOXO1 pathway in immune cells based on direct inhibition of Ubc13 enzymatic acti
175 effective manufacturing process for Si solar cells based on electrodeposition.
176 ses can be manipulated in directing Abs or T cells based on how efficiently the targeted Ag is endocy
177 further commercialization of thin-film solar cells based on hybrid organohalide lead perovskites is i
178                                        Solar cells based on hybrid perovskites have shown high effici
179 be the influence of CD27 and OX40 on human T cells based on in vitro studies and on the phenotypes of
180 ingle-particle fusion in both fixed and live cells based on loss of the mCherry signal.
181  drug sensitivity of single multiple myeloma cells based on measuring their mass accumulation rate (M
182 tic separation (IMS) that typically enriches cells based on one abundant marker.
183 ion between two photobioelectrochemical half-cells based on photosystem 1 and photosystem 2 is invest
184                                        Solar-cells based on Schottky junctions between metals and sem
185 mines the proliferation or quiescence of CRC cells based on the absence or presence of SPDEF.
186 terneurons were discriminated from principal cells based on the autocorrelogram, waveform parameters,
187 of a differential metabolic signature for BC cells based on the BRCA1 functionality.
188 er dimension for NMR detection of biological cells based on the cell type and corresponding particle
189 equires technology for measuring and sorting cells based on the fluorescence levels before and after
190 ities have higher specificity to distinguish cells based on the relative concentrations of their rece
191  measurement and selective sorting of single cells based on the uptake of radiolabeled small molecule
192 f metagene entropy and allows the ranking of cells based on their differentiation potential.
193                                        Solar cells based on this new perovskite show power conversion
194 rotocol for laboratory scale (10 cm(2)) fuel cells based on ultrasonic spray deposition of a standard
195 cursor, progenitor, and fully differentiated cells) based on changes in stage-dependent combinations
196                          We also propose how cells, based on a signal-induced change in cytoplasmic p
197 NO in aqueous solution and in live RAW 264.7 cells, based on the soft nucleophilicity of the phosphin
198 screening strategy that outperforms existing cell-based or biochemical approaches for identifying CRI
199 odels of the adult Drosophila midgut, a stem cell-based organ with known resizing dynamics.
200                               However, human cell-based PanIN models with defined mutations are unava
201 g an isolated target protein or by utilizing cell-based phenotypic assays.
202 ere we use an human-induced pluripotent stem cell-based platform to demonstrate adverse impacts of ob
203 e the authors apply a human pluripotent stem cell-based platform to study the effects of such compoun
204                                      Using a cell-based prion propagation assay, we discovered that t
205 troporation methods for creating therapeutic cell-based products are complex and expensive.
206                          However, the use of cell-based products derived from stem cells as therapeut
207 ries of studies to evaluate its in vitro and cell-based properties.
208                                              Cell-based receptor binding assays confirm that Q8 is a
209 ntal biology, immunology, and embryonic stem cell-based regenerative medicine.
210 f neuroprotection, gene replacement and stem cell-based regenerative paradigms.
211                                      Using a cell-based reporter assay, we screened C4a against a pan
212 ptor activation with low micromolar IC50s in cell-based reporter assays, inhibit Gas6-inducible motil
213                               We developed a cell-based reporter system to quantitate pathogen-specif
214 ies on cells via variable-length tethers for cell-based sandwich ELISA, therefore, provides a sensiti
215                                By developing cell-based SAR and using chemical proteomics, we identif
216                         Using a high content cell-based screen, we identified fibroblast growth facto
217                             A discriminating cell-based screening assay identified compound 001, whic
218                                         In a cell-based screening of pleuromutilin derivatives agains
219    Our approach highlights the power of stem cell-based screens and validation in human forebrain org
220 ent dCas9-TAD, named dCas9-TV, through plant cell-based screens.
221                 Here, we present multiplexed cell-based sensors to simultaneously quantify stress ind
222 ould be a promising cell source for adoptive cell-based SG therapies, and bioengineering of artificia
223                             We then use a 3D cell-based simulation with realistic cell-cell adhesion,
224                     These findings present a cell-based strategy that combines accelerated perfusion
225                                              Cell-based studies have identified several molecular tar
226                                              Cell-based studies indicate that PAGE4 interaction with
227                                              Cell-based studies revealed native-like signaling proper
228                                              Cell-based studies revealed that the synergy site is dis
229 he SDA complex coupled to enzyme kinetic and cell-based studies to provide structure-function propert
230                              Biochemical and cell-based studies using both peptide and protein substr
231                                           In cell-based studies, exon 7-associated variants shifted t
232 nant-negative GusR variants are validated in cell-based studies.
233  RNA using an inducible human embryonic stem cell-based system and microinjection of mouse zygotes.
234 y limits and thus difficult to achieve using cell-based systems.
235 ted with disease states as well as assessing cell-based targeting of effective therapeutic agents.
236                 Next, we optimized a SH-SY5Y cell based tauopathy model by introducing a novel 5-fold
237 ngineering improvements in either soluble or cell-based TCRs for therapeutic purposes.
238        Here, we take advantage of newer stem cell-based technologies to study the mechanisms by which
239  heart disease modeling, drug screening, and cell-based therapeutic applications.
240 search efforts on the implementation of stem cell-based therapeutic strategies in CHD.
241 tective compounds, and provide the basis for cell-based therapeutic strategies.
242 g of natural gene circuits and the design of cell-based therapeutic strategies.
243  properties ideally suit the requirements of cell-based therapeutics, since they permit to characteri
244 vercoming many of the current limitations in cell-based therapeutics.
245 iology to develop innovative engineered stem cell-based therapeutics.
246 success of chimeric antigen receptor (CAR) T-cell based therapies greatly rely on the capacity to ide
247 edical research models and for gene and stem cell based therapies.
248 oth mechanistic studies and screening of new cell based therapies.
249               Clinical trials of bone marrow cell-based therapies after acute myocardial infarction (
250 ogramming, have shown enormous potential for cell-based therapies against intractable diseases such a
251  associated with retinal diseases makes stem-cell-based therapies an attractive strategy for personal
252 d cell manufacturing are poised to broaden T-cell-based therapies and foster new applications in infe
253 ENS; information required for development of cell-based therapies and models of enteric neuropathies.
254                                   RATIONALE: Cell-based therapies are a promising option in patients
255            KEY POINTS: While autologous stem cell-based therapies are currently being tested on elder
256                           Although gene- and cell-based therapies are on the horizon for RP and Usher
257                                              Cell-based therapies are promising alternative therapeut
258                                      Several cell-based therapies are under pre-clinical and clinical
259 g has the potential to enable more-effective cell-based therapies by using readily available cell sou
260          Recent studies have shown that stem cell-based therapies can improve liver function in a mou
261                                         Stem cell-based therapies for Parkinson's disease are moving
262 ion of cell behavior and offering customized cell-based therapies for tissue engineering.
263    Although clinical studies have shown that cell-based therapies improve wound healing, the recruitm
264 Cs may represent a promising alternative for cell-based therapies in AD.
265        Replacing lost retinal cells via stem cell-based therapies is an exciting, rapidly advancing a
266                         Emerging research on cell-based therapies is opening a new door for patients
267 tering A2AR antagonists concurrently with NK cell-based therapies may heighten therapeutic benefits b
268                 Moreover, clinical trials of cell-based therapies present several unique methodologic
269 lls have emerged as potential candidates for cell-based therapies to modulate the immune response in
270              We summarize here the status of cell-based therapies to treat multiple sclerosis and mak
271 ating ARDS, including combination therapies, cell-based therapies, and generic pharmacological compou
272                                              Cell-based therapies, including immunoablation followed
273       These developments, along with novel T cell-based therapies, position us to expand the assortme
274  may impact future design of autologous stem cell-based therapies.
275 tcomes in the treatment of lung disease with cell-based therapies.
276 e potential role of cortical interneurons in cell-based therapies.
277 olled trial) represents the largest study of cell-based therapy for STEMI completed in the United Sta
278  using this method which may further lead to cell-based therapy for treating corneal endothelial dysf
279 d feasibility of the clinical application of cell-based therapy has been demonstrated, and promising
280 On the basis of several preclinical studies, cell-based therapy has emerged as a potential new therap
281 ability, and efficacy of mesenchymal stromal cell-based therapy in pilot clinical trials, including t
282                               Of the various cell-based therapy options, mesenchymal stem/stromal cel
283 elial stem cells for the development of stem cell-based therapy or bioengineering SG tissues to repai
284 vide us with a strong basis for developing T cell-based therapy targeting this shared neoepitope.
285  T cell adoptive transfer may be useful as a cell-based therapy to improve the efficacy and safety of
286      These data suggest that to optimize TR1 cell-based therapy, IL-10 receptor expression has to be
287 tforms for disease study, drug screening and cell-based therapy.
288 the use of hiPSC-CM for disease modeling and cell-based therapy.
289 cells (MSCs) are a promising candidate for a cell-based therapy.
290  has been a long-standing challenge for stem cell-based tissue engineering.
291 ng for tissues, cell cultures, and even stem cell-based tissue regeneration.
292 sly growing mouse incisor as a model of stem cell-based tissue renewal, we found that the transcripti
293 gand-dependent LBD stabilization assays, and cell-based transactivation measurements delineate struct
294 ficant step towards a new generation of stem cell-based treatment for heart failure.
295 nts with a greater likelihood of response to cell-based treatment.
296 ges in inputs and even predict the fate of a cell based upon its signalling history and state.
297 ach capable of high throughput separation of cells based upon surface molecule adhesion.
298 stant inflammation) and ineffectiveness of T-cell-based vaccines against H pylori.
299 r elimination of latent HIV-1 infection by T cell-based vaccines.
300  aimed toward the development of effective B cell-based vaccines.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top